Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of Vibrio alginolyticus collagenase in Peyronie's disease
2023-509621-45-00Phase 2Authorised
- Sponsor
- Fidia Farmaceutici
- Start
- Apr 2025
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of vibrio alginolyticus collagenase in Peyronie's disease (3 arms), sponsored by Fidia Farmaceutici. Primary endpoints: Overall safety and tolerability profile and maximum tolerated dose and Percentage reduction in maximal penile curvature deformity. Planned start Apr 2025; status: authorised.
02
Drugs
vibrio alginolyticus collagenase
03
Conditions
Peyronie's disease
Beyond the preview
Go deeper on 2023-509621-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509621-45-00.